^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies

Published date:
11/29/2018
Excerpt:
...a WES-based analysis of paired CLL DNA samples isolated from 6 R/R CLL patients...confirmed the presence of the amp(1q23) as acquired at relapse after venetoclax in 3 out of 6 patients...venetoclax, a first-in-class BCL-2 inhibitor, leads to response in about 80% of patients with relapsed/refractory (R/R) CLL.
DOI:
10.1182/blood-2018-99-118604